Have a feature idea you'd love to see implemented?
Let us know!
PSTV Plus Therapeutics Inc
Price (delayed)
$1.2
Market cap
$7.08M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.27
Enterprise value
$9.25M
Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique nanotechnology platform
Highlights
The EPS has surged by 62% year-on-year and by 22% since the previous quarter
PSTV's revenue has soared by 53% YoY and by 3.9% QoQ
The quick ratio has plunged by 62% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of PSTV
Market
Valuations
Earnings
Shares outstanding
5.9M
Market cap
$7.08M
Enterprise value
$9.25M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.62
Revenue
$5.73M
EBIT
-$9.16M
EBITDA
-$8.35M
Free cash flow
-$11.4M
Per share
Balance sheet
Liquidity
EPS
-$2.27
Free cash flow per share
-$1.45
Book value per share
-$0.88
Revenue per share
$0.73
TBVPS
$0.78
Total assets
$6.98M
Total liabilities
$12.15M
Debt
$3.4M
Equity
-$5.17M
Working capital
-$6.75M
Debt to equity
-0.66
Current ratio
0.44
Quick ratio
0.4
Net debt/EBITDA
-0.26
Margins
Efficiency
Dividend
EBITDA margin
-145.9%
Gross margin
100%
Net margin
-225.1%
Operating margin
-256%
Return on assets
-146.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
-159.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PSTV stock price
How has the Plus Therapeutics stock price performed over time
Intraday
0.84%
1 week
-4.76%
1 month
-14.29%
1 year
-34.43%
YTD
-31.43%
QTD
-17.81%
Financial performance
How have Plus Therapeutics's revenue and profit performed over time
Revenue
$5.73M
Gross profit
$5.73M
Operating income
-$14.66M
Net income
-$12.89M
Gross margin
100%
Net margin
-225.1%
PSTV's revenue has soared by 53% YoY and by 3.9% QoQ
Plus Therapeutics's gross profit has surged by 53% YoY and by 3.9% QoQ
PSTV's net margin is up by 44% year-on-year and by 6% since the previous quarter
PSTV's operating margin is up by 36% year-on-year
Growth
What is Plus Therapeutics's growth rate over time
Valuation
What is Plus Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.62
The EPS has surged by 62% year-on-year and by 22% since the previous quarter
The equity is up by 32% since the previous quarter
PSTV's revenue has soared by 53% YoY and by 3.9% QoQ
The P/S is 10% above the last 4 quarters average of 1.5
Efficiency
How efficient is Plus Therapeutics business performance
The ROA has plunged by 62% YoY and by 15% from the previous quarter
The return on sales has surged by 59% year-on-year and by 7% since the previous quarter
Dividends
What is PSTV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PSTV.
Financial health
How did Plus Therapeutics financials performed over time
Plus Therapeutics's total assets is 43% lower than its total liabilities
The quick ratio has plunged by 62% YoY and by 11% from the previous quarter
Plus Therapeutics's current ratio has plunged by 60% YoY and by 12% from the previous quarter
PSTV's debt is 166% greater than its equity
The debt to equity has dropped by 138% year-on-year and by 47% since the previous quarter
The equity is up by 32% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.